Home › Funds › BALANCE CAPITAL PARTNERS L.P. › BLTE
BALANCE CAPITAL PARTNERS L.P. position in BLTE
BELITE BIO INC · Health Care
BALANCE CAPITAL PARTNERS L.P. reported holding 22,500 shares of BLTE (BELITE BIO INC) in its Q2 2026 13F filing — a position valued at US$3.5M, representing 2.49% of its reported portfolio and ranking #5 among its reported holdings. BALANCE CAPITAL PARTNERS L.P. has disclosed BLTE holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How BALANCE CAPITAL PARTNERS L.P.'s BLTE position evolved
BALANCE CAPITAL PARTNERS L.P. first disclosed a stake in BLTE in Q1 2026 at 14,500 shares (US$2.3M). The position peaked in Q2 2026 at 22,500 shares, worth US$3.5M. Across 2 filings, BALANCE CAPITAL PARTNERS L.P. increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 22,500 shares valued at US$3.5M — an increase of 8,000 shares quarter over quarter.. Notable position changes include a 55% increase in Q2 2026 (shares rose 10% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 14.50K | $2.31M | New |
| Q2 2026 | 22.50K | $3.46M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BLTE and 13F data
BLTE (BELITE BIO INC) is a Health Care company. 68 other funds we track also report a position in BLTE — the largest reported positions include Darwin Global Management, Ltd. (US$456.6M), Paradigm Biocapital Advisors LP (US$189.8M), RTW INVESTMENTS, LP (US$110.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BLTE
- Darwin Global Management, Ltd. 3.08M sh · $456.59M · Q2 2026
- Paradigm Biocapital Advisors LP 1.23M sh · $189.84M · Q2 2026
- RTW INVESTMENTS, LP 715.33K sh · $110.15M · Q2 2026
- Maverick Capital 396.31K sh · $61.03M · Q2 2026
- MAVERICK CAPITAL LTD 396.31K sh · $61.03M · Q2 2026
- EVENTIDE ASSET MANAGEMENT, LLC 390.83K sh · $60.18M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 357.20K sh · $55.00M · Q2 2026
- Logos Global Management LP 250.00K sh · $38.50M · Q2 2026
- Affinity Asset Advisors, LLC 165.00K sh · $25.41M · Q2 2026
- MPM BioImpact LLC 137.21K sh · $21.13M · Q2 2026
- Patient Square Capital LP 110.00K sh · $16.94M · Q2 2026
- Artia Global Partners LP 24.99K sh · $3.85M · Q2 2026
More on BALANCE CAPITAL PARTNERS L.P.
FAQ
How long has BALANCE CAPITAL PARTNERS L.P. held BLTE?
BALANCE CAPITAL PARTNERS L.P. has disclosed BLTE holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is BALANCE CAPITAL PARTNERS L.P.'s current position in BLTE?
As of Q2 2026, BALANCE CAPITAL PARTNERS L.P. holds 22.50K shares of BLTE (BELITE BIO INC), valued at $3.46M, representing 2.49% of its reported portfolio and ranking #5.
Has BALANCE CAPITAL PARTNERS L.P. been buying or selling BLTE?
In the latest 13F filing (Q2 2026), BALANCE CAPITAL PARTNERS L.P. increased its position in BLTE. The position peaked in Q2 2026 at 22.50K shares.
Which other funds hold BLTE?
Other major institutional holders of BLTE include Darwin Global Management, Ltd., Paradigm Biocapital Advisors LP, RTW INVESTMENTS, LP, among 68 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.